Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) EBT Margin (2018 - 2023)

Denali Therapeutics has reported EBT Margin over the past 6 years, most recently at 7841.59% for Q3 2023.

  • Quarterly EBT Margin fell 493912.0% to 7841.59% in Q3 2023 from the year-ago period, while the trailing twelve-month figure was 33119.49% through Jun 2024, down 3308205.0% year-over-year, with the annual reading at 43.93% for FY2023, 25661.0% up from the prior year.
  • EBT Margin was 7841.59% for Q3 2023 at Denali Therapeutics, down from 62.35% in the prior quarter.
  • Over five years, EBT Margin peaked at 77.53% in Q4 2020 and troughed at 7004100.0% in Q1 2021.
  • The 5-year median for EBT Margin is 986.84% (2022), against an average of 380452.33%.
  • Year-over-year, EBT Margin crashed -700249814bps in 2021 and then surged 700394220bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 1236.26% in 2019, then soared by 106bps to 77.53% in 2020, then crashed by -882bps to 606.01% in 2021, then crashed by -63bps to 986.84% in 2022, then crashed by -695bps to 7841.59% in 2023.
  • Per Business Quant, the three most recent readings for DNLI's EBT Margin are 7841.59% (Q3 2023), 62.35% (Q2 2023), and 312.4% (Q1 2023).